OSD
Over the past year, the global oral solid dose (OSD) market has continued its steady growth, with an estimated value of USD 36.50 billion in 2023 that is projected to grow at a compound annual growth rate (CAGR) of 5.97% from 2024 to 2030 [1].
Driven by an expanding and ageing global population, the growth of the OSD market has been accompanied by a number of evolving trends that demand adaptability and innovation from pharmaceutical manufacturers to navigate, including:
- The rise in oral biologics
Fuelled by the desire for more patient-centric biologic administration options compared with traditional injectable formats, the biopharma industry is increasingly exploring the potential of oral biologics. This trend is particularly notable with the emergence of GLP-1 receptor agonists, which offer a convenient oral route for managing chronic conditions like diabetes. As research and development in this area continue to advance, we can anticipate a broader range of oral biologics entering the market, offering patients more accessible and user-friendly treatment options.
- A preference for long-term partnerships with integrated CDMOs
Reflecting a desire to streamline operations and reduce reliance on multiple suppliers, pharmaceutical companies are increasingly seeking long-term partnerships with contract development and manufacturing organisations (CDMOs) that can offer integrated solutions across various stages of drug development.
- A growing reliance on digital solutions
The increasing complexity of drug development and the rising need for data-driven decision-making are driving a greater reliance on digital solutions. These tools offer valuable support in areas such as material characterisation, process simulation and statistical analysis, enabling a more efficient and robust approach to OSD formulation and manufacturing.
In an interview at CPHI Milan 2024 with Pharmaceutical Technology® Europe, Uwe Hanenberg, Head of Product Implementation at Recipharm explored these key trends shaping the OSD market. Leveraging his unique insight, he also examined how pharma’s increasing focus on sustainability and energy-efficient technologies and growing interest in continuous manufacturing solutions and impacting the OSD space.
References: